34589983|t|A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib.
34589983|a|Most patients with NSCLC, initially sensitive, will develop resistance after a period of time after the application of ALK inhibitors. We present here a rare LOC285000-ALK-NCK2 gene fusion with response to crizotinib treatment; the patient achieved a progression-free survival of 23 months.
34589983	10	29	Lung Adenocarcinoma	Disease	MESH:D000077192
34589983	47	56	LOC285000	Gene	285000
34589983	57	60	ALK	Gene	238
34589983	61	65	NCK2	Gene	8440
34589983	146	156	Crizotinib	Chemical	MESH:D000077547
34589983	163	171	patients	Species	9606
34589983	177	182	NSCLC	Disease	
34589983	277	280	ALK	Gene	238
34589983	316	325	LOC285000	Gene	285000
34589983	326	329	ALK	Gene	238
34589983	330	334	NCK2	Gene	8440
34589983	364	374	crizotinib	Chemical	MESH:D000077547
34589983	390	397	patient	Species	9606
34589983	Negative_Correlation	MESH:D000077547	MESH:D000077192
34589983	Association	238	285000
34589983	Association	MESH:D000077192	285000
34589983	Association	238	8440
34589983	Association	285000	8440
34589983	Negative_Correlation	MESH:D000077547	238
34589983	Negative_Correlation	MESH:D000077547	8440
34589983	Negative_Correlation	MESH:D000077547	285000
34589983	Association	MESH:D000077192	238
34589983	Association	MESH:D000077192	8440

